GlassScriptPhysician profile
Terry Horton
NPI 1871570986
$7,001.79
in general payments reported to CMS, 2019-2025
42 companies · $1,169 in 2025
The $1,169 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $761 · 2021: $1,475 · 2022: $851 · 2023: $1,121 · 2024: $945 · 2025: $1,169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,235.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $717.45 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $621.93 | 2019-2025 | Airsupra, Farxiga, Bevespi Aerosphere |
| Glaxosmithkline, LLC. | $489.77 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $456.28 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $435.12 | 2019-2024 | Jardiance |
| Amgen INC. | $412.90 | 2019-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $400.09 | 2021-2025 | |
| Lilly USA, LLC | $398.60 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $366.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $265.44 | 2022-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $262.93 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $199.53 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $198.15 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $190.15 | 2019-2022 | |
| Lundbeck LLC | $168.64 | 2024-2025 | Rexulti |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Horton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.